Manufacturing

Manufacturing

R-Pharm’s production designed with account to all latest GMP requirements, which is unprecedented for Russia, especially for the production of aseptic injection drug formulations.

Новости

«Р-Фарм» принял участие в Форуме стратегических инициатив

«Р-Фарм» принял участие в Форуме стратегических инициатив

21-22 июля на ВДНХ состоялся Форум стратегических инициатив, посвященный формированию концепции долгосрочного социально-экономического развития России до 2035 года. Группа компаний «Р-Фарм» представила на форуме стенд своих достижений, сотрудники компании приняли участие в деловой программе.

July 27, 2016

R-Pharm Group Completes Development of Drug for Treatment of Epilepsy

news

There has been finished the analysis of clinical findings of antiepileptic drug, i.e. valproic acid. The research findings proved the equivalence of the generic drug designed for the treatment of various forms of epilepcy and the foreign original. By 2017 R-Pharm group plans to register the drug in the Russian Federation and to start commercial production at a modern manufacturing facility in Russia that meets the international quality standards.

July 12, 2016

R-Pharm Brings to Market Antipsychotic Drug

news

R-Pharm group has received marketing authorization ЛП-003560 dd. 12.04.2016 issued by Ministry of Health of the Russian Federation for Periciazine drug. The drug is an antipsychotic agent and it belongs to phenothiazine class of the piperidine group designed for the treatment of acute and chronic psychotic disorders.

July 5, 2016

Big Step is Taken Towards Cure of Patients Suffering from Chronic Hepatitis C

Big Step is Taken Towards Cure of Patients Suffering from Chronic Hepatitis C

Brystol Myers Squibb company and R-Pharm group concluded an agreement on allocation of production of Daclatasvir, an innovative highly efficient drug for the treatment of the chronic hepatitis C, at R-Pharm manufacturing facilities.

June 30, 2016

R-Pharm Participates in Forum “PHARMA AND BIOTECH 2016: Storage of Thermolabile Drugs – Three Levels of Regulation”

news

On May 31st, in Moscow there took place the International Forum V “Pharma and Biotech 2016: Storage of Thermolabile Drugs – Three Levels of Regulation” organized for the experts of the pharm sector and veterinary medicine who specialize in questions related to the development of the market of thermolabile drugs and products in Russia. Director of R-Pharm Healthcare Economics Alexander Bykov was among the participants of the Forum. The representative of the company took on moderating duties at the roundtable discussion on the topic “Prospects of extension of the restrictive lists. The role of medical technologies evaluation system”. During the roundtable discussion the focus was on the following topics: the current procedure of revision of drug lists, the role of medical technologies evaluation system, the role of localization, revision of the lists initiated by the Ministry of Healthcare of the Russian Federation and others. The head of medical technologies evaluation and standardization laboratory at Burnazyan State Scientific Center of FMBA Pavel Vorobyov was the principal speaker of the roundtable discussion. He told the participants about methods of evaluation of medical technologies.

June 29, 2016
News Archive →